PER® Chemotherapy Foundation Symposium (CFS)

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer.

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

The kinase inhibitors sorafenib and lenvatinib have significantly altered the treatment paradigm for patients with advanced radioactive iodine-refractory differentiated thyroid cancer in both older and younger populations.

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

While the prognosis remains good for individuals with HPV-positive oropharyngeal cancers, the incidence of these cancers continues to rise, and researchers are currently seeking less intense treatment options that are equally effective but not as toxic for patients.

The use of neoadjuvant chemotherapy in advanced ovarian cancer continues to increase, even though the practice has not been shown to improve survival versus primary cytoreduction.

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Monoclonal antibodies are poised to revolutionize the treatment of adult patients with relapsed acute lymphoblastic leukemia, specifically blinatumomab and inotuzumab ozogamicin.

Optimizing outcomes with novel antibodies in multiple myeloma will involve combination regimens with established agents.

The landscape for the diagnosis and treatment of polycythemia vera (PV) is changing, and that's good news for patients and practitioners who can look to improvements ahead.

C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.

B-cell pathway inhibitors have shown impressive survival benefits for patients with chronic lymphocytic leukemia, but require careful monitoring and possible suspension to control adverse events.

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer

Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.

In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.

When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what's ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.

The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms

As the targeted therapy era in chronic lymphocytic leukemia (CLL) continues to unfold, two next-generation agents are generating responses with improved safety profiles as single agents and in combination regimens

The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a toll-like receptor 3 (TLR) 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma